Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Rooney

Showing results (81-90 of 165) with videos related to

Pageof 17
Sort By:
Oncotarget|December 8, 2017
Bioenergetics of acquired cisplatin resistant H1299 non-small cell lung cancer and P31 mesothelioma cellsFintan Geoghegan, Robert J Buckland, Eric T Rogers, et al.
Australian and New Zealand Journal of Ophthalmology|May 1, 1989
Tinted lenses and dyslexics--a controlled study. SPELD (S.A.) Tinted Lenses Study GroupG A Gole, S N Dibden, C C Pearson, et al.
The Journal of Infectious Diseases|September 17, 2002
Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patientsGail Skowron, Daniel R Kuritzkes, Melanie A Thompson, et al.
Eclinicalmedicine|May 27, 2021
Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled TrialAndrea R Thurman, Jill L Schwartz, Mackenzie L Cottrell, et al.
AIDS (London, England)|September 24, 2011
Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infectionRichard H Haubrich, Sharon A Riddler, Heather Ribaudo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 30, 2025
Pharmacokinetics of Twice-Daily Tenofovir Alafenamide In Adults with HIV-Associated TB on BIC/FTC/TAF and RifampicinEmmanuella Chinonso Osuala, Ivan Nicholas Nkuhairwe, Marothi Peter Letsoalo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2001
Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infectionR Snoeck, M Bossens, D Parent, et al.
Antiviral Research|May 1, 1986
Double-blind comparison of weekend and daily regimens of oral acyclovir for suppression of recurrent genital herpesS E Straus, M Seidlin, H E Takiff, et al.
Cancer Treatment Reports|December 1, 1987
Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patientsR M Lowenthal, C N Chesterman, J D Griffiths, et al.
HIV Clinical Trials|May 14, 2008
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIVAnn C Collier, Camlin Tierney, Gerald F Downey, et al.
Pageof 17

Showing results (81-90 of 165) with videos related to

Sort By:
Pageof 17
Oncotarget|December 8, 2017
Bioenergetics of acquired cisplatin resistant H1299 non-small cell lung cancer and P31 mesothelioma cellsFintan Geoghegan, Robert J Buckland, Eric T Rogers, et al.
Australian and New Zealand Journal of Ophthalmology|May 1, 1989
Tinted lenses and dyslexics--a controlled study. SPELD (S.A.) Tinted Lenses Study GroupG A Gole, S N Dibden, C C Pearson, et al.
The Journal of Infectious Diseases|September 17, 2002
Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patientsGail Skowron, Daniel R Kuritzkes, Melanie A Thompson, et al.
Eclinicalmedicine|May 27, 2021
Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled TrialAndrea R Thurman, Jill L Schwartz, Mackenzie L Cottrell, et al.
AIDS (London, England)|September 24, 2011
Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infectionRichard H Haubrich, Sharon A Riddler, Heather Ribaudo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 30, 2025
Pharmacokinetics of Twice-Daily Tenofovir Alafenamide In Adults with HIV-Associated TB on BIC/FTC/TAF and RifampicinEmmanuella Chinonso Osuala, Ivan Nicholas Nkuhairwe, Marothi Peter Letsoalo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2001
Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infectionR Snoeck, M Bossens, D Parent, et al.
Antiviral Research|May 1, 1986
Double-blind comparison of weekend and daily regimens of oral acyclovir for suppression of recurrent genital herpesS E Straus, M Seidlin, H E Takiff, et al.
Cancer Treatment Reports|December 1, 1987
Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patientsR M Lowenthal, C N Chesterman, J D Griffiths, et al.
HIV Clinical Trials|May 14, 2008
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIVAnn C Collier, Camlin Tierney, Gerald F Downey, et al.
Pageof 17